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abstract
Clinical trials in oncology are an emergent field in sub-Saharan Africa. There is a long history of clinical trials in
high-income countries (HICs), with increasing attempts to develop patient-centric approaches and to evaluate
patient-centered outcomes. The challenge remains as to how these trends could be adopted in low-resource
settings and adapted to best fit the different health ecosystems that coexist on the African continent. Models that
evaluate patient-related outcomes and measures and that are used in HICs must be modified, adopted, and
adapted to suit the diverse populations and the low-resource settings in most of the continent. Patient en-
gagement in clinical trials in Africa must be well nuanced, and it demands innovation and application of models
that consider established but tailored notions/principles of patient and community engagement and the unique
sociocultural aspects of different populations. It also must be linked to strategies that aim to improve patient
education, health literacy, and access to services and to encourage and protect patient autonomy.
JCO Global Oncol 6:942-947. © 2020 by American Society of Clinical Oncology
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INTRODUCTION
Clinical trials in oncology are an emergent field in sub-
Saharan Africa. There is a long history of clinical trials
in high income countries (HICs), with increasing at-
tempts to develop patient-centric approaches and to
evaluate patient-centered outcomes. The challenge
remains as to how these trends could be adopted in
low-resource settings and adapted to best fit the dif-
ferent health ecosystems that coexist on the African
continent.
Clinical research is aimed at improvement in health
and well-being. Conversely, more than 85% of re-
search investment is perceived as wasted, and its
outcome frequently is viewed as of little or no relevance
to policymakers, practitioners, and even patients.1,2
Patient engagement in clinical research is regarded
now as central to improving the return of investments
and research outcomes. Patients bring in their rich
experiences throughout the cancer trajectory. The
incorporation of these experiences enables re-
searchers to identify priority areas and to align the
conception, design, conduction, and analysis of
clinical trials to maximize benefit, avoid waste, and
achieve real-world impact.
At the core of this rests the fundamental under-
standing of what truly constitutes patient-centric
care. This type of care is defined by the US Institute of
Medicine as “Providing care that is…… responsive to
individual patient preferences, needs, and values,
and ensuring that patient values guide all clinical
decisions.”3 Understanding how clinical trials can
enhance patient engagement is an undertaking that
can be learned from previous experiences in different
health ecosystems.
Equally pivotal is the understanding of the role of
patients in clinical trials. This is behind the no-
tion that the patients want to know, in addition
to wanting to be known. A successful strategy to
implementing research would aim to address (1)
how to manage fear, thus encouraging recruitment,
and (2) how to foster comfort and trust, thus en-
suring retention.
PATIENT ENGAGEMENT IN HIGH-RESOURCE COUNTRIES
In developed countries, with a long history of clinical
trials, there has been a concerted effort to improve
patient input. This effort mainly has centered around
health-related quality of life for trial participants/sur-
vivors. This effort is part of a bigger shift in patient
management that reports patient-reported outcomes.4
Although traditional surgical interventions, for in-
stance, may have clearly demarcated end points
like margin status or number of nodes, these end
points do not adequately capture the patient’s ex-
perience of surgery. Chemotherapeutic end points,
like tumor regression or a complete pathologic re-
sponse, again fail to capture the lived experience of
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the patient going through these treatment strategies
and their potential long-term adverse effects, such
as neuropathy, functional impairment, and financial
toxicity.5,6
Involving patients in clinical trials empowers them to get
involved in their health and helps even out the balance of
power. This encourages patients to go beyond the passive
role and engage in active dialogues that bring about
transformation and improvement in the health care expe-
rience. Viewed through this lens, the research process is
about conducting a research with the patient rather than
about, to, or for the patient.7
Engaging patients would help researchers know the proper
questions to ask and what outcomes to assess and would
inform good-quality data. After patients have information,
they are likely to participate in clinical trials; therefore,
recruitment is faster and more patients are retained. The
patients also serve as advocates for friends and families to
participate in more clinical trials.8,9 Involving patients in
clinical trials also improves patient safety and increases
risk-reduction efforts.10
The interpretation of patient-centered outcomes, such as
PROMIS,6 involves a measurement or evaluation of
a number of domains. A frequent ongoing challenge is the
determination of what may constitute a minimally important
difference that is likely to alter patient care or clinician
practice.11,12 One of the oldest established outcomes is
the European Organization for Research and Treatment of
Cancer outcome scores,13 which have been well validated
in different populations and may serve as a potential
template through which we can attempt to interpret the
opportunities and challenges one might face in adapting to
the African context.
CLINICAL TRIALS IN AFRICA
The clinical trial is not a new concept in Africa. Though
trials are not conducted as robustly in African as in HICs,
the development of clinical trials in Africa traditionally has
occurred mainly in the setting of infectious diseases, like
HIV and tuberculosis. This is not unexpected, given that
the previous public health focus has been on infectious
diseases. With the increase of diagnoses of cancers and
other noncommunicable diseases, the public health focus
is expanding, and critical lessons could be obtained from
the experiences obtained in this space. The paucity of
clinical trials on the continent has been attributed to the
costs, complexity, and legal requirements required to run
clinical trials.14 The cost of medications used in trials and
the ability of populations to access these drugs have been
additional barriers.15 There are little data specifically on
patient engagement in these trials, but strategies to en-
hance retention, including use of technology to send
messages, have been used with varying degrees of
success.16-18
ONCOLOGY TRIALS IN LOWER- TO MIDDLE-INCOME
COUNTRIES: STATUS AND OPPORTUNITIES FOR
PATIENT ENGAGEMENT
Clinical trials in oncology in Africa are a fairly nascent
concept, but the emerging field of patient-reported out-
comes is starting to get traction. A number of studies on the
continent have attempted to validate the EORTC outcome
scores in their populations; studies out of Morocco and
Ethiopia suggest a successful validation of the tool, al-
though the application of it is not widespread.19, 20 There
also have been attempts in Kenya to develop clinical trials
that address the health-related quality of life after lym-
phedema for patients with Kaposi sarcoma.20a There has
been a drive to consolidate efforts to improve clinical trials
in Africa. There has been a considerable improvement in
collaborations across multidisciplinary teams of biomedical
scientists, leading to increased sharing of resources and
infrastructure needed to conduct clinical trials. For in-
stance, the Consortium for Advanced Research Training in
Africa is a collaboration comprised of 13 academic in-
stitutions and research institutions across Africa aimed at
facilitating and enhancing research along priority areas for
countries in Africa and at increasing the pipeline of re-
search scientists and their collective output. The Prostate
Cancer Transatlantic Consortium of Nigeria has more than
15 institutions and 50 investigators in Nigeria. This group
has established regional hubs to help improve access of
researchers to funding opportunities, including external
extramural funding, such as US National Institutes of
Health grants. In southern Africa, the medical research
council provides a regional hub for the training of re-
searchers in clinical trials.
Efforts to enhance research capacity and infrastructure are
also underway through developing collaborations with
multiple stakeholders, including governments, not-for-
profit organizations, academic institutions, and pharma.
For instance, BIO Ventures for Global Health, a nonprofit
global health organization, launched the African Access
Initiative, which is a program that brings together oncology
companies with governments and hospitals in Africa to
foster cancer research and improve access to cancer
treatment. Poor access to drugs is a major deterrent to
completion of treatment and a cause of catastrophic health
expenditure for patients, so these collaborations have
helped improve provision of care to patients. In addition,
the African Access Initiative has launched the African
Consortium for Cancer Clinical Trials to develop cancer
clinical trials led by investigators in Africa. This group aims
to improve access to clinical trials for African patients and
to develop the infrastructure, personnel, laboratories, and
more to help support clinical trials. They also are en-
couraging their pharmaceutical partner companies and
biomedical firms to invest in drug research and develop-
ment in Africa. These efforts, along with other regional
efforts, like the Clinton Health Access Initiative, through its
Patient-Centered Approaches for Clinical Trials in Africa
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partnership with local governments and the American
Cancer Society, have increased the access to cancer drugs
and treatment.
There are opportunities to broaden the scope of clinical
trials and think beyond traditional existing models. There is
an expanding role for community-based/participatory re-
search, which could serve to create synergies with the
traditional clinical trial model. The researcher must start to
think about how to move the clinical trial out of the hospital
and into the community, where the people are. As we
embrace the increasing shift toward pragmatic trials, this
starts to become increasingly relevant in the African con-
text. However, this demands that the researcher adopts
a less observational role. It also demands that the re-
searcher start to think creatively and broadly about how
clinical trials could serve as potential vehicles to help
strengthen health systems. This would involve engaging
with multiple stakeholders up front and leveraging preex-
isting systems; for instance, antenatal clinics could be used
as a an entry portal for clinical trials in maternal and child
health but also could be explored to see how systems and
services in that unit could be improved.
In all efforts, value to the community and to the health
system must be demonstrated consistently. Though one
might be limited by the scope of funding, one always needs
to consider the real-world setting in which the research is
engaged. One cannot set up a laboratory that only serves to
look at the blood values of patients in the study or only
at specific parameters in a patient’s blood and ignore the
fact that the patient may require additional evaluation for
a coexistent condition. Instances have been reported in
which state-of-the-art laboratories have been constructed
in hospital units but only serve study patients, while the rest
of the patients at the hospital have to travel long distances
for laboratory services. The ethics of this continue to be
called into question. No one is suggesting that the re-
searcher should take on the role of policy maker and
provide universal coverage, but one could certainly explore
ways to increase the value of services by engaging with
policy makers upfront. Engaging stakeholders and building
critical steps that help to actively improve care as a result of
one’s research is an imperative that we as clinical re-
searchers should start to engage in actively.
CHALLENGES OR BARRIERS TO PATIENT ENGAGEMENT IN
LOWER- TO MIDDLE-INCOME COUNTRIES
A number of challenges or barriers exist in sub-Saharan
Africa that could potentially hinder the wholesale impor-
tation of models that work in HICs without due consider-
ation for the social cultural nuances that may come into play
when engaging with different health ecosystems.
The concept of vulnerability in clinical research is more
defined in HICs though still debated.21 However, traditional
definitions of vulnerability, such as level of literacy, poverty,
and lack of access to medications and services, would
place a substantial portion of patients with cancer in lower-
to middle-income countries (LMICs) in the categories of
vulnerable populations. There currently is no consensus
about the definition of vulnerability in LMICs, and many
ethical considerations would need to be delineated
according to the changing landscape of societies in a state
of transition—in addition to the recent considerations re-
lated to the problematic and harmful consequences of
offshoring of clinical trials in Latin America, Africa, and
other developing countries.22,23
The current preexistent patient-centered models demand
a different level of health literacy and perhaps numeracy. In
one country for instance, more than 40 local dialects may
coexist. Patients may not necessarily be well versed with the
national languages, which may form an additional hin-
drance to general literacy about health. Though health
literacy is improving slowly, a considerable proportion of
patients in many countries may come from rural settings
and often may have little or no formal education. These low
general literacy levels have a bearing on subsequent health
literacy. This then begs the question of how one can design
a trial model that is readily comprehensible to populations
served and that respects the ethics of patient autonomy and
dignity.
Patients frequently must travel long distances to access
definitive care; as a result, a significant number of patients
are unable to complete or frequently default on their
treatment. Therefore, follow-up of patients is particularly
challenging in the African setting. In addition, a number of
populations are pastoral or migratory, which poses another
challenge to patient engagement and retention. For in-
stance, in unpublished data derived from a 5-year pro-
spective breast cancer study conducted in Kenya, an initial
recruitment of approximately 500 patients at a tertiary re-
ferral hospital showed that the follow-up rate at 2 years
accounted for only approximately 60 patients.
Though technology presumably helps address some of
these gaps through the development of digital solutions,
there may also be certain drawbacks. For instance, with the
Kenyan cohort, despite getting the mobile contacts of
patients, the next of kin and family friends, patients
themselves, and their other contacts frequently changed
their numbers and often were untraceable. Even as we
propose technologic advances as a potential panacea to
address problems of recruitment and retention, we should
start to think more profoundly about what other funda-
mental barriers to retention exist and what policies or in-
novative strategies could be used to overcome some of
these hurdles.
As researchers, we must look inward and reflect on what
viewpoints we bring to the table that could potentially in-
crease our retention of patients. Incorporating the lens of
health disparities research presents a corollary that could
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help anticipate challenges and provide a roadmap on how
best to interpret the ongoing needs of populations studied
in Africa.
As a researcher, a lack of knowledge about target com-
munities generally is the first hurdle that many clinicians
face. A lack of understanding of the data or perceptions
around a particular community frequently will result in
misunderstandings about the nature of research con-
ducted. In addition, a lack of assessment of community
needs, be they health literacy as already described or the
unique culture of the community, will serve as stumbling
blocks to patient engagement. For instance, in a number of
societies, the approach to health decision making involves
a collectivism approach. This means that health decisions
are made as a group rather than by the individual. Engaging
in a direct discussion with patients may not necessarily
ensure automatic buy in unless discussed at the primary
locus of decision making, which could be the immediate
family, clan, or broader community. Inability to appreciate
these nuances could result in dismal recruitment.
In addition, if one fails to define and attempt to address
what the priorities of the patient or community are, it would
be difficult to get buy in and engagement from these
communities. A study on the adverse effects of chemo-
therapy, for instance, may be of interest to the researcher,
but if the researcher fails to take on board the frequent
pharmacy supply shortages leading to a lack of antinausea
medication that could decrease compliance, then the re-
cruitment outcome should not be unexpected. In addition,
it is important to address the sociocultural barriers, such as
stigma, that could act as barriers to care. University
graduates in Uganda were reluctant to receive chemo-
therapy at a national referral center for fear of being
identified as having cancer.24 The social fallout from
a cancer diagnosis also must be considered. Data from
Nigeria show a high correlation of family disintegration after
a diagnosis of cancer: a divorce rate of approximately 40%
was seen in patients with breast cancer within 3 years.25
Inability to address these fears, whether it is fear of losing
a breast, fear of losing hair, or family disintegration, will
ensure that recruitment and compliance to treatment are
likely to be persistent concerns. Failing to build trust in
a community, either through outsourcing of patient activ-
ities to nonengaged third parties, insufficient or nonexistent
outreach staffing, or minimal commitment to consistent
community presence will serve to destroy trust in a com-
munity setting.
ROLE OF RESEARCH ADVOCACY
As the clinical research system in Africa develops, re-
search advocacy—loosely defined as patient advocates
and their representatives meaningful engaged in the re-
search system—which is a relatively new concept and
activity on the continent, is taking root as a significant
component in the overall research structure. That is, the
current state of development of the research system and
the simultaneous rise of patient advocacy are consistent
and necessary for the development of strong, active,
meaningful research advocacy. In a research system that
supports patient advocacy, specifically research advocacy,
there are increasing opportunities for patient engagement.
In fact, as research advocates become more prepared and
competent and as research advocacy becomes more
significantly embedded in national and local research
systems, there will be corresponding growth in opportu-
nities for both patient engagement in research and influ-
ence on research.
Ongoing mechanisms and avenues for preparation are
essential such that advocates will be ready to act on/take
advantage of the opportunities to engage in research.
This is in order for research advocacy to reach its po-
tential to influence and help reshape cancer research,
and thus for it to positively affect the cancer survival and
survivorship landscape in Africa.
THE UNIQUE PERSPECTIVES OF PATIENT ADVOCATES
IN RESEARCH
Just as clinicians and researchers bring specific expertise
and value to the research process, patients engaged in
research bring unique lived expertise and value—essential
to development and monitoring of research systems re-
sponsive to local and regional patient needs, cultures, and
imperatives.25 The role of research advocacy is highlighted
in Table 1.
SPECIFIC ADVOCACY OPPORTUNITIES
The types, routes, and extent of engagement will vary by
region, country, culture, and people as well as by maturity
of the research system and of patient advocacy. However,
by learning from and generously borrowing from research
advocacy as it has developed in the United States and other
TABLE 1. Roles of Research Advocacy
Research Advocate Roles
Strengthen the research process/system
Change the way researchers see patients and consider patient
needs
Keep patients at the center of research thinking and conduct
Put faces on the disease and keep patients at the center
Give voice to all patients and survivors (These voices are unique,
experience based, and indispensable)
Ask questions specific to the authentic experience of cancer
journeys
Create a sense of urgency—by the advocate’s very presence
Elevate the importance of survivorship (how well one lives), the
companion of survival (how long one lives)
Form mutually respectful and beneficial partnerships with
researchers
Provide hope
Patient-Centered Approaches for Clinical Trials in Africa
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countries, advocates in Africa will engage in research in
numerous ways, including the following:
• on research grant review panels
• on institutional review boards (which are required for
research involving humans and must have community
membership)
• on government health- and cancer-related panels and
board
• in research studies (as study participants or research
team members)
• in community-based participatory research26
• as community representatives for local research sites
• with legislative bodies to affect funding and policy.
Both the actual opportunities to serve and the types of
service will be tailored to the region and the population.
That is, African advocates will cocreate, with others
engaged in their unique research systems, appropriate,
meaningful spaces and opportunities to most effectively
serve within the context of their own environment, re-
sources, needs, and other imperatives. Research advo-
cacy in Africa is not simply international advocacy with an
African face.
In conclusion, patient engagement in clinical trials in
Africa must be well-nuanced engagement that demands
that we innovate and apply a model that considers
established but tailored notions/principles of patient en-
gagement and the unique sociocultural aspects of dif-
ferent populations. It also must be linked to strategies that
aim to improve patient education and health literacy and
that encourage and protect patient autonomy. There is
great anticipation that these patient-centered efforts will
inform and engage both the patient and the research
communities relative to the educational, psychological,
and environmental needs of patients in creating a truly
patient-centric imperative that meets the patient’s need to
know and to be known in Africa.
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